Last $35.93 USD
Change Today -0.24 / -0.66%
Volume 423.5K
DXCM On Other Exchanges
Symbol
Exchange
DXCM is not on other exchanges.
As of 5:20 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

dexcom inc (DXCM) Snapshot

Open
$34.92
Previous Close
$36.17
Day High
$36.39
Day Low
$34.67
52 Week High
03/6/14 - $49.83
52 Week Low
07/31/13 - $21.76
Market Cap
2.7B
Average Volume 10 Days
768.2K
EPS TTM
$-0.41
Shares Outstanding
74.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DEXCOM INC (DXCM)

dexcom inc (DXCM) Related Businessweek News

No Related Businessweek News Found

dexcom inc (DXCM) Details

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. It offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. The company’s ambulatory product line includes SEVEN PLUS, DexCom G4 system, and DexCom G4 PLATINUM system for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments, as well as DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring. Its in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. The company also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. It markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. The company was founded in 1999 and is headquartered in San Diego, California.

646 Employees
Last Reported Date: 02/20/14
Founded in 1999

dexcom inc (DXCM) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $420.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $325.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $237.0K
Chief Technical Officer
Total Annual Compensation: $284.9K
Executive Vice President of Strategy and Corp...
Total Annual Compensation: $284.9K
Compensation as of Fiscal Year 2013.

dexcom inc (DXCM) Key Developments

Dexcom, Inc. Receives U.S. Food and Drug Administration Approval for its Dexcom G4(R) PLATINUM Professional CGM

Dexcom, Inc. announced that it has received U.S. Food and Drug Administration (FDA) approval for its Dexcom G4(R) PLATINUM Professional CGM. It is the only professional-version CGM that offers real-time, unblinded feedback allowing the patient to experience the full benefits of real-time CGM, while providing the doctor with an opportunity to review glucose data retrospectively with the patient to make therapeutic treatment recommendations. Clinicians can use the insights gained from a professional CGM session to adjust therapy and to educate and motivate patients to modify their behavior after viewing the effects that specific foods, exercise, stress, and medications have on their glucose levels. Current professional CGMs offer only retrospective, blinded information but with the Dexcom G4 PLATINUM Professional system, physicians can help coach their patients to better outcomes through real-time visibility of dynamic glucose changes as they occur. Professional CGM is a powerful, analytical tool for healthcare professionals to help their patients who: Struggle to meet glycemic goals; suffer from frequent hypoglycemia; and have wide fluctuations in glycemic variability. The Dexcom G4(R) PLATINUM Professional CGM consists of a medical practice-owned professional CGM system and sensors. With minimal training and setup time, patients are placed on a professional CGM for a period lasting seven days. During that time, dynamic and comprehensive data is collected and can be shared with the patient, which aids in their understanding of the impact between behavior and glucose activity. By taking at least two calibrations from a blood glucose meter daily, the Dexcom G4(R) PLATINUM Professional CGM provides continuous readings on the rate and direction of glucose change up to every five minutes; and supports therapy adjustments and treatment recommendations made by their healthcare practitioner. The system can also be customized for glucose targets and alerts, and has an alarm feature to alert the user if glucose levels rise or fall to dangerous levels.

DexCom, Inc. Presents at William Blair & Company's 34th Annual Growth Stock Conference, Jun-11-2014 02:40 PM

DexCom, Inc. Presents at William Blair & Company's 34th Annual Growth Stock Conference, Jun-11-2014 02:40 PM. Venue: Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States. Speakers: Steven R. Pacelli, Executive Vice President of Strategy and Corporate Development.

DexCom, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 04:30 PM

DexCom, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 04:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Kevin R. Sayer, President, Chief Operating Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DXCM:US $35.93 USD -0.24

DXCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Insulet Corp $38.12 USD -0.16
Merge Healthcare Inc $2.25 USD -0.01
NeuStar Inc $26.44 USD -0.09
Radview Software Ltd $0.0040 USD -0.0001
Tandem Diabetes Care Inc $13.97 USD -0.26
View Industry Companies
 

Industry Analysis

DXCM

Industry Average

Valuation DXCM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.9x
Price/Book 30.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEXCOM INC, please visit www.dexcom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.